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Background: Bromelain and N-acetylcysteine are two natural, sulfhydryl-containing compounds with good safety
profiles which have been investigated for their benefits and application in health and disease for more than fifty
years. As such, the potential values of these agents in cancer therapy have been variably reported in the literature.
In the present study, the efficacy of bromelain and N-acetylcysteine in single agent and combination treatment
of human gastrointestinal carcinoma cells was evaluated in vitro and the underlying mechanisms of effect were
explored.
Methods: The growth-inhibitory effects of bromelain and N-acetylcysteine, on their own and in combination,
on a panel of human gastrointestinal carcinoma cell lines, including MKN45, KATO-III, HT29-5F12, HT29-5M21
and LS174T, were assessed by sulforhodamine B assay. Moreover, the influence of the treatment on the
expression of a range of proteins involved in the regulation of cell cycle and survival was investigated by
Western blot. The presence of apoptosis was also examined by TUNEL assay.
Results: Bromelain and N-acetylcysteine significantly inhibited cell proliferation, more potently in combination
therapy. Drug-drug interaction in combination therapy was found to be predominantly synergistic or additive.
Mechanistically, apoptotic bodies were detected in treated cells by TUNEL assay. Furthermore, Western blot
analysis revealed diminution of cyclins A, B and D, the emergence of immunoreactive subunits of caspase-3,
caspase-7, caspase-8 and cleaved PARP, withering or cleavage of procaspase-9, overexpression of cytochrome c,
reduced expression of anti-apoptotic Bcl-2 and pro-survival phospho-Akt, the emergence of the autophagosomal
marker LC3-II and deregulation of other autophagy-related proteins, including Atg3, Atg5, Atg7, Atg12 and Beclin 1.
These results were more prominent in combination therapy.
Conclusion: We report for the first time to our knowledge the growth-inhibitory and cytotoxic effects of bromelain
and N-acetylcysteine, in particular in combination, on a panel of gastrointestinal cancer cell lines with different
phenotypes and characteristics. These effects apparently resulted from cell cycle arrest, apoptosis and autophagy.
Towards the development of novel strategies for the enhancement of microscopic cytoreduction, our results lay the
basis for further evaluation of this formulation in locoregional approaches to peritoneal surface malignancies and
carcinomatosis.
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Gastrointestinal malignancies account for more than one
third of all deaths from cancer worldwide [1]. Repre-
senting the most common gastrointestinal cancers [2],
colorectal and gastric cancers have the potential to
disseminate throughout the peritoneal cavity. Although
known as a manifestation of advanced disease, peritoneal
carcinomatosis is a locoregional cancer spread, with the
peritoneum serving as the first line of defense against the
progression of carcinomatosis [3]. Hence, cytoreductive
surgery in combination with hyperthermic intraperitoneal
chemotherapy [4,5] has brought about long-term survival
to patients with peritoneal surface malignancies [6] and is
a promising approach to peritoneal carcinomatosis of
gastrointestinal origin. However, disruption of the periton-
eal barrier is believed to contribute to the recurrence [3].
Novel modalities are thus needed to complement the
current standard of care through enhancement of micro-
scopic cytoreduction. To this end, our research team at St
George Hospital (Sydney, Australia), with an established
Peritoneal Surface Malignancy Program since 1996
[7,8], has sought to develop novel locoregional ap-
proaches to peritoneal malignancies. As such, a variety
of agents have been tested for their potential value in
such a strategy, among which bromelain and N-
acetylcysteine (NAC) as two natural agents with good
safety profiles have shown promise in our investiga-
tions. We previously described the efficacy of brome-
lain in combination with NAC for in situ lysis of the
mucin secreted in pseudomyxoma peritonei [9]. In the
present article, we report for the first time to our
knowledge that bromelain and NAC, on their own and
more potently in combination, inhibit growth and pro-
liferation of gastrointestinal cancer cells and promote
cell death in vitro.
Methods
Cell culture
Human gastric carcinoma cell lines MKN45 and KATO-III
were obtained from the Cancer Research Campaign La-
boratories (University of Nottingham, NG7 2RD, UK) and
the American Type Culture Collection (ATCC, Manassas,
VA, USA), respectively. HT29-5F12 and HT29-5M21 colonTable 1 Bromelain and NAC concentrations used in single age
carcinoma cells
Cell line Single agent Bromelain (μg/mL) Single agent NAC (mM)
MKN45 10 25 50 100 200 400 600 1 5 10 25 50 75
KATO-III 10 50 75 100 200 300 400 1 5 10 25 50 75
HT29-5F12 5 10 20 40 50 - - 1 5 10 25 50 75
HT29-5M21 5 10 20 40 50 - - 1 5 10 25 50 75
LS174T 10 20 30 40 50 - - 2.5 5 10 20 30 40adenocarcinoma cells were a kind gift from Dr Thécla
Lesuffleur (Université Pierre et Marie Curie, Paris, France).
LS174T colon adenocarcinoma cell line was purchased
from Sigma-Aldrich (Sigma-Aldrich, MO, USA). All cell
lines were maintained in a humidified atmosphere of 95%
air and 5% CO2 at 37°C in their respective media as follows:
MKN45 in RPMI-1640 medium, KATO-III in Iscove’s
Dulbecco’s modified Eagle’s medium, HT29-5F12 and
HT29-5M21 in Dulbecco’s modified Eagle’s medium
and LS174T in Minimum Essential Medium Eagle EBSS
medium (all from Invitrogen, Carlsbad, CA, USA). The
culture media used were all supplemented with 10% (v/v)
fetal bovine serum and 1% (v/v) penicillin-streptomycin
(Invitrogen, Carlsbad, CA, USA), with the exception of
Iscove’s Dulbecco’s modified Eagle’s medium being
supplemented with 20% fetal bovine serum. As per the
distributor’s instructions, the culture medium for LS174T
was further supplemented with 2 mM Glutamine and 1%
Non-Essential Amino Acids (NEAA).
Drug preparation
Bromelain and NAC were purchased from Sigma-Aldrich
(Sigma-Aldrich, MO, USA). The stock solutions were
freshly made with bromelain and NAC being dissolved
in relevant culture media at concentrations of 1 mg/
mL and 1 M, respectively. Cisplatin was solubilized in
dimethylformamide (DMF) at concentration of 0.05 M
and the stock solution was stored at 4°C. Stock solu-
tions were filtered, pH adjusted (applicable for NAC)
and diluted with appropriate medium according to the
final treating concentrations required for single agent
and combination treatment groups.
Sulforhodamine B assay
The effect of bromelain and NAC on growth and pro-
liferation of the cells was determined by sulforhoda-
mine B assay. In brief, cells were seeded into 96-well
plates at densities of 1500–5000 cells/well. At desired
confluence, cells were treated for 72 hours with brome-
lain (5–600 μg/mL) and NAC (1–100 mM), as well as with
cisplatin (0.01–50 μM) as the positive control. For com-
bination therapy, cells were individually treated with three
selected concentrations of each agent and nine possiblent and combination treatment of gastrointestinal
Combinations (Bromelain/NAC)
- 50/1 50/5 50/10 75/1 75/5 75/10 100/1 100/5 100/10
100 50/1 50/5 50/10 100/1 100/5 100/10 200/1 200/5 200/10
- 5/1 5/5 5/10 10/1 10/5 10/10 20/1 20/5 20/10
- 5/1 5/5 5/10 10/1 10/5 10/10 20/1 20/5 20/10
- 10/5 10/10 10/20 20/5 20/10 20/20 30/5 30/10 30/20
Figure 1 (See legend on next page.)
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Figure 1 Sulforhodamine B assay on MKN45, KATO-III, HT29-5F12, HT29-5M21 and LS174T cells after single agent treatment with
bromelain and NAC. As assayed 72 hours post treatment, concentration-dependent inhibition of cell proliferation was observed with
escalating concentrations of bromelain (left panel) and NAC (right panel). Cisplatin was used as the positive control of the experiment
(small graphs a-e). Significant changes (p <0.05) are marked by asterisks.
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the treatment, cells were fixed by 30 minute incubation
with 10% (w/v) trichloroacetic acid at 4°C. After five
washes, plates were stained with 0.4% (w/v) sulforhoda-
mine B (Sigma-Aldrich) dissolved in 1% acetic acid. Un-
bound dye was removed by rinsing the plates with 1%
acetic acid and bound sulforhodamine B was then solubi-
lized with 10 mM Tris base (Sigma-Aldrich, MO, USA).
Using the PowerWaveX™ microplate scanning spectro-
photometer (Bio-Tek Instruments Inc., Winooski, VT,
USA), absorbance was read at the working wavelength
of 570 nm.
Fifty percent inhibitory concentration and drug-drug
interaction analyses
Fifty percent inhibitory concentration (IC50) values were
calculated from concentration-response curves plot-
ting growth percentage versus drug concentration
using GraphPad Prism 6 (GraphPad Software Inc., San
Diego, CA, USA). The interaction between the drugs
in combination treatment was determined by the me-
dian effect analysis using CalcuSyn software (Biosoft,
Cambridge, UK) and the combination index (CI) was
calculated based on the drug concentration and cell
viability. CIs less than 0.9 and greater than 1.1 were
considered as synergism and antagonism, respectively,
and those between 0.9 and 1.1 as additivity.
Western blotting
The efficacy of bromelain and NAC in inducing growth
arrest and cell death was explored in MKN45, KATO-
III, and LS174T cells using Western blot analysis of the
relevant expressions 48 hours post-treatment. Briefly,
cells were homogenized in Radio-Immunoprecipitation
Assay (RIPA) lysis buffer containing 10% protease inhibi-
tor (Sigma-Aldrich, MO, USA) and the extracted protein
concentration was quantified by BioRad protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). After protein
separation by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and transfer to polyvinylidene
fluoride membranes (Millipore, Bedford, MA, USA),
the following primary antibodies were applied accord-
ing to the manufacturers’ protocols: rabbit polyclonal
anti-caspase 3, anti-Bcl2 (Santa Cruz Biotechnology,
CA, USA), anti-caspase 8 (R & D Systems, MN,
USA), anti-caspase 9, anti-PARP, anti-cytochrome c,anti-Akt, anti-LC3, anti-Atg3, anti-Atg5, anti-Atg7 and
anti-Atg12; rabbit monoclonal anti-caspase 7, anti-Bcl-xl,
anti-phospho-Akt, anti-Beclin 1, anti-cyclin B1 and anti-
cyclin D2; mouse monoclonal anti-cyclin A2 and anti-
cyclin E1 (Cell Signaling Technology Inc., MA, USA). A
similar process was carried out for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as the loading
control using the mouse monoclonal anti-GAPDH
antibody (Sigma-Aldrich, MO, USA). Membranes were
then washed and treated with appropriate horseradish
peroxidase-conjugated secondary antibodies (Cell Signaling
Technology Inc). The antigen-antibody reaction was
visualized using ImageQuant™ LAS 4000 Biomolecular
imager and ImageQuant™ software (GE Healthcare,
Chalfont, UK).
TdT-mediated dUTP nick-end labeling assay
The presence of apoptosis in MKN45 and LS174T cells
was determined by terminal deoxynucleotidyl transferase
(TdT)-mediated deoxyuridine triphosphate (dUTP) nick-
end labeling (TUNEL) assay using DeadEnd™ Fluoromet-
ric TUNEL System (Promega, WI, USA) in accordance
with the manufacturer’s instructions. In brief, cells were
seeded onto sterile glass coverslips in 6-well plates,
allowed to grow for 72 hours and then treated for
48 hours. Cells were washed twice with ice-cold phos-
phate buffered saline (PBS), fixed in 4% methanol-free
formaldehyde in PBS for 25 minutes at 4°C and perme-
abilized by 0.1% Triton X-100 (Sigma-Aldrich, MO,
USA) in PBS for 5 minutes (fixed cells incubated for
5 minutes with DNase I buffer and treated with 5.5–10
units/mL of DNase I (Ambion, Life Technologies, MA,
USA) for 10 minutes were used as positive controls).
After being washed, cells were covered with 100 μL
of Equilibration Buffer for 5-10 minutes at room
temperature and treated with 50 μl of recombinant
terminal deoxynucleotidyl transferase (rTdT) incuba-
tion buffer at 37°C for 60 minutes inside the humidi-
fied chamber (cells incubated with an incubation
buffer without rTdT enzyme were used as negative
controls). The tailing reaction was then terminated by
immersing the slides in 2X saline-sodium citrate (SSC)
buffer for 15 minutes at room temperature. Unincorpor-
ated fluorescein-12-dUTP was removed by PBS washes
and cells were stained with 1 μg/mL propidium iodide in
PBS for 15 minutes at room temperature in the dark.
Figure 2 Concentration-response curves for single agent treatment of MKN45, KATO-III, HT29-5F12, HT29-5M21 and LS174T cells with
bromelain and NAC. These curves plot growth percentage versus drug concentration after 72 h treatment of the cancer cells with bromelain
(left panel) and NAC (right panel). Half maximal inhibitory concentration (IC50) values are demonstrated for each curve individually.
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Figure 3 Combination treatment of MKN45, KATO-III, HT29-5F12, HT29-5M21 and LS174T cells with bromelain and NAC. Cells were
treated for 72 hours with three concentrations of each agent on their own and in combination. In general, growth-inhibitory effects of
combination therapy were significantly more potent than those induced by single agent treatment. Significant changes (p <0.05) are
marked by bold (*) and non-bold (*) asterisks when single agent bromelain and NAC are considered as control, respectively.
Amini et al. Journal of Experimental & Clinical Cancer Research 2014, 33:92 Page 7 of 15
http://www.jeccr.com/content/33/1/92Coverslips were washed in deionized water for 5 minutes
at room temperature for a total of three times and
mounted with gelatin glycerol. Cells were visualized by
FluoView™ Laser Scanning confocal microscope (Olympus,
Center Valley, PA, USA) and X60 oil immersion lens using
a standard fluorescein filter set to view the green fluores-
cence of fluorescein at 520 ± 20 nm and the red fluores-
cence of propidium iodide at >620 nm. The FluoView™
software version 4.3 (Olympus, Center Valley, PA, USA)
was used to overlay the images.
Statistical analysis
All data presented are representative of three independent
experiments. Statistical analyses were performed using
GraphPad Prism 6 (GraphPad Software Inc., San Diego,
CA, USA). The Student’s t-test was applied for unpaired
samples. p values <0.05 were considered significant.
Results
Bromelain and NAC, on their own, significantly inhibited
proliferation of the human gastric and colon carcinoma
cells studied
First, antiproliferative effects of bromelain and NAC in sin-
gle agent therapy was evaluated by sulforhodamine B assay
(Figure 1). Bromelain significantly inhibited proliferation of
MKN45 (p = 0.0018, 0.0010, 0.0002 and <0.0001 for con-
centrations of 100, 200, 400 and 600 μg/mL, respectively),
KATO-III (p <0.0001 for concentrations ≥100 μg/mL),
HT29-5F12, HT29-5M21 (p <0.0001 for concentrations of
40 and 50 μg/mL) and LS174T cells (p <0.0001 for concen-
trations ≥30 μg/mL) in a concentration-dependent manner.
Similarly, NAC exerted antiproliferative effects on MKN45
(p = 0.0006 and 0.0037 for concentrations of 5 and 10 mM,
respectively, and p <0.0001 for concentrations of 25, 50 and
75 mM), KATO-III (p = 0.0071 and 0.0004 for concen-
trations of 25 and 50 mM, respectively, and p <0.0001
for concentrations of 75 and 100 mM), HT29-5F12
(p = 0.0003 for concentration of 10 mM and p <0.0001
for concentrations ≥25 mM), HT29-5M21 (p = 0.0091
and 0.0008 for concentrations of 5 and 10 mM, re-
spectively, and p <0.0001 for concentrations ≥25 mM)
and LS174T cells (p = 0.0026 for concentration of
10 mM and p <0.0001 for concentrations ≥20 mM)
in a concentration-dependent manner. As shown in
Figure 2, IC50 values of 94, 142, 30, 34 and 27 μg/mL
for bromelain and IC50 values of 15, 57, 15, 16 and22 mM for NAC were resulted from treating MKN45,
KATO-III, HT29-5F12, HT29-5M21 and LS174T cells,
respectively.
Combined use of bromelain and NAC resulted in
significantly more potent growth-inhibitory effects
Subsequently, we investigated how bromelain and NAC
influence growth and proliferation of the cancer cells in
combination therapy. We treated the cells with three se-
lected concentrations of each agent individually and nine
possible combinations of the two. Our data revealed that
in most combination groups, growth-inhibitory effects
resulted were significantly more potent than those in-
duced by single agent bromelain and/or NAC (Figure 3).
In agreement, analysis of the concentration-response
curves revealed a left-sided shift in combination therapy
(Figure 4, left panel).
Synergy was the predominant pattern of bromelain-NAC
interaction in combination therapy
Next, the interaction between the drugs in combination
therapy was determined by the median effect analysis
using the CalcuSyn software (Figure 4, right panel). In
MKN45 cells, the interaction pattern changed from an-
tagonism, observed only in the combination groups with
the lowest concentration of bromelain, to additivity and
synergism as the bromelain concentration increased. In
KATO-III cells, synergistic effects were evident in all
treatment groups, except for two groups with the lowest
concentration of NAC (additive and antagonistic effects
when NAC 1 mM used in combination with bromelain
50 and 100 μg/mL, respectively) whereby consistent
strengthening of the synergy accompanied higher con-
centrations of bromelain/NAC. Apart from the antagon-
istic effects observed in two groups with the lowest
concentration of NAC (NAC 1 mM combined with bro-
melain 5 and 10 μg/mL), bromelain-NAC interaction in
HT29-5F12 cells was revealed to be synergistic, with a
slight strengthening at higher concentrations. With no
antagonism and only one additive pattern observed with
the lowest concentrations of bromelain and NAC, drug-
drug interaction was mainly synergistic in HT29-5M21
cells, with a fairly slight fluctuation in the potency
as concentrations rose. Finally, in LS174T treatment
groups, increases in the bromelain concentration were
associated with resultant progress in interaction with
Figure 4 (See legend on next page.)
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Figure 4 Concentration-response curves and drug-drug interaction analysis of combination treatment of MKN45, KATO-III, HT29-5F12,
HT29-5M21 and LS174T cells. Left panel demonstrates left-sided shift of concentration-response curves of NAC after being used in combination
with bromelain. Drug-drug interaction analysis (right panel) revealed synergism and additivity as the predominant patterns of interaction between
bromelain and NAC in combination therapy.
Amini et al. Journal of Experimental & Clinical Cancer Research 2014, 33:92 Page 9 of 15
http://www.jeccr.com/content/33/1/92NAC from antagonism (bromelain 10 μg/mL combined
with NAC 10 and 20 mM and bromelain 20 μg/mL
combined with NAC 5 mM) to additivity and slight
synergism. On the other hand, with the exception of one
instance (bromelain 20 μg/mL with NAC 5 mM), rises
in NAC concentration resulted in the weakening of
interaction with a given concentration of bromelain.Bromelain/NAC treatment interfered with cell cycle
progression and induced cell death with involvement of
both apoptotic and autophagic processes
Following the efficacy study, we investigated the
mechanistic basis of the growth-inhibitory effects in-
duced by bromelain and NAC using MKN45 and
LS174T cell lines. To this end, we first conducted
fluorometric TdT-mediated dUTP nick-end labeling
(TUNEL) assay to explore the presence of apoptosis
after 48 hours of treatment with bromelain and NAC,
on their own and in combination. As anticipated,
apoptotic bodies were detected in both cell lines as an
indication of DNA fragmentation and activated apop-
totic cascades. Figure 5 depicts the results for MKN45
cells, representatively.
To further explore the underlying mechanisms of ef-
fect, we then analyzed the expression of a variety of
proteins involved in the regulation of cell growth and
vitality in MKN45, KATO-III and LS174T cells after
single agent and combination therapy with bromelain
and NAC. For this purpose, Western blot analysis was
performed after 48 hours on treated cells as well as on
their untreated counterparts as the negative control.
As apparent from MKN45 blots shown as our repre-
sentative results in Figure 6, treatment with bromelain
and NAC appeared to inhibit cell survival and to
induce apoptotic and autophagic cell death while
interfering with cell cycle progression. Firstly, the ex-
pression of the cell cycle regulatory proteins cyclin A,
cyclin B and cyclin D was found to be diminished in
treated cells. Secondly, activation of caspase system
was evident as the emergence of immunoreactive sub-
units of caspase-3, caspase-7 and caspase-8, withering
or cleavage of procaspase-9, and overexpression of
cytochrome c. The functionality of activated caspase-3
was also confirmed by the emergence of cleaved
poly (ADP-ribose) polymerase (PARP). Meanwhile, the
expression of antiapoptotic Bcl-2 and phosphorylationof prosurvival Akt were shown to be attenuated.
Finally, autophagy apparently contribute to cell death
as increased expression of the autophagosomal marker
LC3-II was detected along with deregulated expression
of other autophagy-related proteins, including Atg3,
Atg5, Atg7, Atg12 and Beclin-1. In general, these find-
ings were more prominent in combination therapy.
Similar results were obtained with KATO-III and
LS174T cells (data not shown).Discussion
Bromelain is a crude, aqueous extract from the pine-
apple comprised of sulfhydryl-containing proteolytic
enzymes as the main constituents, and a variety
of non-proteolytic enzymes and components [10,11].
Being available as a pharmaceutical product since
1956 [12], bromelain has shown benefits in digestion,
wound healing, burn debridement, and enhancement
of antibiotic absorption. Immunomodulatory, anti-
coagulative and anti-inflammatory activities of brome-
lain with potential applications in various pathological
conditions, including infections, cardiovascular and
respiratory diseases and musculoskeletal injuries, have
been reported [13,14]. Moreover, anticancer properties
of bromelain have been shown in different studies
[15]. N-acetylcysteine (NAC), known as a sulfhydryl
group donor naturally found in Allium plants, is the
acetylated derivative of the amino acid L-cysteine and
a precursor to the powerful antioxidant glutathione.
Initial studies in 1960s and 1970s reported clinical
benefits of NAC as an effective mucolytic agent in cys-
tic fibrosis [16] and an antidote for acetaminophen
overdose hepatotoxicity [17]. Since then, its utility in
different pathological conditions, e.g. chronic ob-
structive pulmonary disease, contrast-induced ne-
phropathy, cardiovascular diseases, neuropsychiatric
disorders and cancer, has been investigated [18,19].
Both drugs are considered as inexpensive, well-
tolerated agents with good safety profiles.
We found in the present study that bromelain and
NAC exert cytotoxic effects on a panel of human
gastrointestinal cancer cells of different origin, chemo-
sensitivity and phenotype. MKN45 and KATO-III are
gastric cancer cell lines classified as poorly differenti-
ated and signet ring carcinoma cells, respectively.
HT29-5F12 and HT29-5M21 are two subpopulations
Figure 5 (See legend on next page.)
Amini et al. Journal of Experimental & Clinical Cancer Research 2014, 33:92 Page 10 of 15
http://www.jeccr.com/content/33/1/92
(See figure on previous page.)
Figure 5 Fluorometric TdT-mediated dUTP nick-end labeling (TUNEL) assay on treated MKN45 cells. After 48 hours of treatment with
bromelain (100 and 200 μg/mL), NAC (5 and 10 mM) or the combination, cells were assayed for TUNEL reactivity and viewed under laser
scanning confocal microscope. Green (fluorescein-12-dUTP) and red (propidium iodide) fluorescence correspond to fragmented DNA and the
nucleus, respectively, indicating the presence of apoptotic cells in all treatment groups as compared with DNase I-treated cells used as the
positive control. Scale bar: 50 μm.
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fluorouracil and methotrexate, respectively. LS174T is
a colon adenocarcinoma cell line with a goblet cell-
like phenotype. Furthermore, apart from the unified
expression of the membrane-associated mucin MUC1,
these cells exhibit different expression phenotypes
with respect to the gastrointestinal secretory mucins.
While MKN45 and KATO-III both represent a pre-
dominantly gastric phenotype and specifically express
MUC5AC [20], HT29-5F12 and HT29-5M21 mainly
express MUC2 and MUC5AC, respectively [21], and
LS174T expresses the goblet cell-specific mucins MUC2,
MUC5AC and MUC6 [22].
Anticancer properties of bromelain or NAC, indi-
vidually, have been evaluated in some in vitro and
in vivo models before. Bromelain has shown cytotoxic
and/or cytostatic effects on murine lung carcinoma,
mammary adenocarcinoma, leukemia, lymphoma, sar-
coma, melanoma and ascitic tumor cell lines [23-26],
as well as on human cell lines derived from gastric
and colon carcinoma [23,27,28], glioma [29], breast
cancer [30-32], epidermoid carcinoma, melanoma [33]
and malignant peritoneal mesothelioma [34]. Brome-
lain was also found to induce differentiation of
leukemia cell lines in vitro [35] and to exert chemo-
preventive effects on skin [36-38] and colon [28]
tumorigenesis in vivo. Clinically, however, benefits of
bromelain in cancer have been explored in few studies
[39-42]. NAC has been reported to inhibit growth,
proliferation and/or invasive behavior of human can-
cer cells, including colorectal [43], bladder [44,45],
prostate [46], tongue [47] and lung [48] carcinoma cell
lines, in vitro. In addition, anticarcinogenic [49,50]
and chemoprotective [51] properties of NAC and its
potential value as a chemopreventive agent [52-55] or
a chemoprotectant [56-61] has been investigated.
NAC has also been shown to interact with and
enhance cytotoxic effects of chemotherapeutic drugs
[62,63], interferon α [64], copper [65] and epigallocatechin-
3-gallate [66] on cancer cells. In contrast, few contradictory
reports are also available. Tysnes et al. [29] observed
that bromelain significantly and reversibly reduced ad-
hesion, migration and invasion of glioma cells, but did
not affect cell viability in vitro. In a recent study by
Sceneay et al. [67], while NAC targeted hypoxicresponse of breast cancer cells in vitro, it did not in-
hibit, but even enhanced, tumor growth in vivo. To-
gether, these findings imply that bromelain and NAC
might function in a cell- and/or context-dependent
manner. Examining the efficacy of the two agents in
combination, we interestingly found in the present
study the synergistic and additive interactions between
bromelain and NAC with resultant potentiation of
cytotoxicity in combination therapy. Here, we report
for the first time cytotoxic effects of bromelain and
NAC on gastrointestinal cancer cells with added value
in combination therapy.
Mechanistically, we found that bromelain and
NAC, in particular in combination, inhibit cell cycle
progression and induce both apoptotic and autopha-
gic cell death in the gastrointestinal carcinoma cells.
Orderly progression of the cell cycle from one phase
to another is coordinated by cyclins sequentially
activating their partner proteins, cyclin-dependent ki-
nases (CDKs) [68]. This is initiated by the expression
of cyclin D in early G1 which drives the cell cycle
through to late G1 and followed by subsequent in-
duction of cyclin E, cyclin A and cyclin B at late G1,
early S and late S phases, respectively. Thus, our re-
sults indicating diminution of cyclins D, A and B
suggest that treatment halts cell cycle progression in
early G1. This was found to be associated with acti-
vation of intrinsic and extrinsic caspase-dependent
apoptotic pathways and inhibition of pro-survival
pathways which collectively reduce cell viability. Fi-
nally, autophagy was shown to apparently contribute
to cell death when deregulation of autophagy-related
proteins and, more importantly, an increase in the
expression of LC3-II, known as the most reliable
marker of autophagosomes [69], were observed.
Mechanistic basis for the growth-inhibitory effects of
bromelain or NAC on malignant cells have been ex-
plored in a number of studies. Kalra et al. and Bhui
et al. have demonstrated in their investigations on
mouse skin tumors that bromelain treatment is asso-
ciated with upregulation of p53 and Bax, activation of
caspase 3 and caspase 9, attenuation of Erk and Akt
phosphorylation and decrease in Bcl-2 [37,38]. They
later reported that bromelain treatment of human
epidermoid carcinoma and melanoma cells, in vitro,
Figure 6 (See legend on next page.)
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Figure 6 Western blot analysis of the expression of proteins involved in the regulation of cell cycle and survival in MKN45 cells.
After 48 hours of treatment with single agent or combined bromelain (100 and 200 μg/mL) and NAC (5 and 10 mM), activation of caspase
system (represented by caspase proteins, cytochrome c and PARP), inhibition of anti-apoptotic and pro-survival processes (represented
by Bcl-2 and phospho-Akt), diminution of the cell cycle regulators cyclin A, cyclin B and cyclin D along with the emergence of the
autophagosomal marker LC3-II and deregulation of other autophagy-related proteins, including Atg3, Atg5, Atg7, Atg12 and Beclin 1,
were found. As seen, results were more prominent in combination therapy. Our data implies that growth arrest, apoptosis and autophagy
are likely mechanisms underlying cytotoxic effects of bromelain and NAC on gastrointestinal cancer cells. GAPDH was used as the
loading control.
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http://www.jeccr.com/content/33/1/92resulted in cell cycle arrest at G(2)/M phase (by
modulation of cyclin B1, phospho-cdc25C, Plk1,
phospho-cdc2 and myt1) and subsequent induction
of apoptosis through modulation of Bax-Bcl-2 ratio,
apoptotic protease activating factor 1 (Apaf-1), caspase-9,
and caspase-3 [33]. In a separate study on breast cancer
cells in vitro, they demonstrated induction of apop-
tosis and autophagy in response to bromelain where
autophagy preceded and facilitated apoptotic response
[30]. Bromelain-induced apoptosis in breast [31,32]
and colon cancer cells [28] has also been supported by
other investigators.
As reviewed by De Flora et al. [70], NAC utilizes a
variety of mechanisms to inhibit carcinogenesis. NAC
has been shown to inhibit 12-O-tetradecanoylphorbol-
13-acetate (TPA)-mediated induction of cyclin D1 and
DNA synthesis [71], to diminish DNA synthesis in
human astrocytoma cells [72], to inhibit p38 mitogen-
activated protein kinase (MAPK) activation and ab-
normal cell cycle progression in human lymphoma
cells [73], and to induce CDK inhibitors and G1 cell
cycle arrest in murine papilloma cells [74]. More-
over, despite a large body of evidence establishing
anti-apoptotic effects of NAC protecting normal cells
against cytotoxic stimuli, there are reports arguing
for a pro-apoptotic role of NAC. As an initial obser-
vation, Tsai et al. [75] reported that NAC induce
apoptosis in aortic smooth muscle cells but not in
endothelial cells. In agreement, Liu et al. [76] and Havre
et al. [77] indicated that NAC selectively induced p53-
mediated apoptosis in several oncogenically-transformed fi-
broblasts, but not in normal cells. In a study by
Nargi et al. [43], it was demonstrated in a range of
colorectal cancer (CRC) cell lines that NAC differen-
tially induced cell cycle arrest or apoptosis in CRC
cells and identified CDK inhibitor p21(WAF1/Cip1),
functional p53, Ras status and basal levels of reactive
oxygen species (ROS) in CRC cells as important de-
terminants of susceptibility to apoptosis. Cho et al.
also found that NAC reduced ROS production and
Akt phosphorylation in breast cancer cells, resulting
in apoptotic cell death [78]. NAC has also been
shown to enhance H2O2-, UV- and MK886-inducedapoptosis of murine hybridoma [79], human melan-
oma [80] and human T-cell leukemia cells [81],
respectively. These reports and our findings conclu-
sively support the notion that NAC can exert pro-
apoptotic effects in a cell type- and context-dependent
manner.Conclusion
In summary, we found in the present study that bro-
melain and NAC, on their own and more potently in
combination, inhibit growth, proliferation and survival
of human gastrointestinal cancer cells of different phe-
notypes and characteristics. Our data suggests that
bromelain in combination with NAC could be of po-
tential value in novel therapeutical approaches to can-
cer. With special regard to peritoneal malignancies
and carcinomatosis, this formulation holds promise
for enhancement of microscopic cytoreduction in
locoregional strategies and thus represents an interest-
ing avenue for future research.Abbreviations
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